Effect of Abdominal Obesity on Lipoprotein Metabolism
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Abdominal obesity is strongly associated with dyslipidemia, which may account for the associated increased risk of atherosclerosis and coronary disease. Weight reduction is suggested to be a preferred and effective first-line strategy to correct lipid abnormalities, particularly in overweight/obese subjects. This improvement may be related to the effect of reduction in abdominal fat mass on apoB and apoA-I metabolism, but this remains to be fully demonstrated.
Hypothesis: Reduction in abdominal fat mass by weight loss decreases apoB concentration and raises HDL-cholesterol chiefly by increasing LDL-apoB fractional catabolic rate (FCR), as well as decreasing HDL apoA-I, respectively.
| Condition | Intervention | Phase |
|---|---|---|
|
Obesity Dyslipidemia Insulin Resistance |
Behavioral: Weight loss by dietary restriction |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effect of Weight Loss on Lipoprotein Metabolism in Abdominal Obesity |
- Primary: Fractional catabolic and production rates of LDL-apoB and HDL-apoA-I (before and after 16 week treatments)
- Secondary: Cholesterol; Triglyceride; LDL-cholesterol; Adipocytokines; Genetic polymorphism
| Estimated Enrollment: | 40 |
| Study Start Date: | January 1995 |
| Estimated Study Completion Date: | December 1998 |
We examined the mechanism of the effect of weight loss through dieting on LDL and HDL metabolism in abdominally obese men. LDL apoB-100 and HDL apoA-I kinetics were studied using a primed-constant infusion of 1-[13C]-leucine in a controlled, dietary intervention trial of 16 weeks duration in middle-aged, obese men with the metabolic syndrome. Isotopic enrichment in apoB and apoA-I was measured by gas chromatography-mass spectrometry and fractional turnover rates estimated using multi-compartmental modelling.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Obesity was defined as a body mass index (BMI) >28kg/m2 and visceral visceral obesity (waist to hip ratio> 1.0 or waist circumference >100 cm)
Exclusion Criteria:
- Diabetes mellitus,
- Proteinuria,
- Hypothyroidism,
- Abnormal liver enzymes,
- Major systemic illness,
- A history of alcohol abuse,
- A family history of hyperlipidemia or premature coronary artery disease or were taking medication known to affect lipid metabolism.
Contacts and Locations| Australia, Western Australia | |
| Royal Perth Hospital | |
| Perth, Western Australia, Australia, 6000 | |
| Principal Investigator: | Dick C Chan, PhD | The University of Western Australia |
| Study Chair: | Gerald F Watts, MD | The University of Western Australia |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00438061 History of Changes |
| Other Study ID Numbers: | EC-256 |
| Study First Received: | February 20, 2007 |
| Last Updated: | February 23, 2007 |
| Health Authority: | Australia: Human Research Ethics Committee |
Keywords provided by The University of Western Australia:
|
Lipoprotein metabolism Cardiovascular disease Obesity |
Additional relevant MeSH terms:
|
Insulin Resistance Obesity Dyslipidemias Obesity, Abdominal Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Lipid Metabolism Disorders |
ClinicalTrials.gov processed this record on May 19, 2013